Racial and ethnic trends in prostate cancer incidence and mortality in Philadelphia, PA: An observational study

Related News

• 

  When Segregation of Opioid Use Disorder Treatment Threatens Care for People with Coexisting Conditions

  Life becomes very complex for patients who need to manage pain due to cancer or other illness while still receiving methadone treatment for opioid use disorder (OUD). Methadone is a highly effective medication for treating OUD, however, the current U.S. regulatory framework mandates that methadone for OUD is exclusively accessible through federally approved Opioid Treatment Programs, with many individuals required to make daily visits for supervised dosing. This requirement places a significant burden on those with competing health needs, limited access to transportation, living in rural areas or in regions with few or no treatment programs.

• 

  This Week In the Archives

  This week the Bates Center staff started preparing for an exhibit on Black hospitals and nurse training schools in Philadelphia. Click to learn more about what we’re working on!

• 

  Penn Nursing and Annenberg School for Communication Partner with Camden County to Launch Virtual Reality Narcan Training

  Last year, 354 people died from opioid overdoses in Camden County, according to the New Jersey Office of the Attorney General, which in 2022 recorded an estimated 15,407 administrations statewide of naloxone, also known by the brand name Narcan. This year, New Jersey launched an initiative allowing anyone 14 and older to anonymously obtain naloxone for free at more than 600 participating pharmacies across the state. Camden County, just across the Delaware River from Philadelphia, has also installed secure NaloxBoxes in every public school.